Hartaj Singh
Stock Analyst at Oppenheimer
(2.05)
# 2,795
Out of 4,784 analysts
102
Total ratings
40.62%
Success rate
-9.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Outperform | $115 → $132 | $111.79 | +18.08% | 14 | Mar 4, 2025 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $0.30 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $5.70 | +391.23% | 6 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,150 → $1,000 | $637.36 | +56.90% | 12 | Nov 6, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $306.97 | +95.46% | 7 | Oct 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $550 → $540 | $492.69 | +9.60% | 16 | Oct 30, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $31.12 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.27 | +687.40% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $2.30 | +2,508.70% | 5 | May 30, 2024 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $180 | $70.41 | +155.65% | 9 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.89 | +376.19% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.73 | +2,212.14% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $9.56 | +130.13% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.11 | +58,458.56% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $20.32 | +47.64% | 1 | Jan 26, 2018 |
Gilead Sciences
Mar 4, 2025
Maintains: Outperform
Price Target: $115 → $132
Current: $111.79
Upside: +18.08%
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.30
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $5.70
Upside: +391.23%
Regeneron Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $1,150 → $1,000
Current: $637.36
Upside: +56.90%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $306.97
Upside: +95.46%
Vertex Pharmaceuticals
Oct 30, 2024
Maintains: Outperform
Price Target: $550 → $540
Current: $492.69
Upside: +9.60%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $31.12
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.27
Upside: +687.40%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $2.30
Upside: +2,508.70%
Sarepta Therapeutics
May 14, 2024
Upgrades: Outperform
Price Target: $180
Current: $70.41
Upside: +155.65%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.89
Upside: +376.19%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.73
Upside: +2,212.14%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $9.56
Upside: +130.13%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.11
Upside: +58,458.56%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $20.32
Upside: +47.64%